Your shopping cart is currently empty

Ro 41-5253 is an orally active RARα antagonist, ligand, and partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ. It exhibits antitumor activity, inhibits proliferation, and induces apoptosis in MCF-7 and ZR-75.1 estrogen receptor-positive breast cancer cells.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $52 | - | In Stock |
| Description | Ro 41-5253 is an orally active RARα antagonist, ligand, and partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ. It exhibits antitumor activity, inhibits proliferation, and induces apoptosis in MCF-7 and ZR-75.1 estrogen receptor-positive breast cancer cells. |
| Targets&IC50 | RARα:60 nM, RARγ:3.3 μM, RARβ:2.4 μM |
| In vitro | In human breast cancer cell lines MCF-7 and ZR 75.1, Ro 41-5253 (1 nM-10 μM; for 10 days) inhibited cell growth. At a concentration of 10 μM, the inhibition rate of MCF-7 cell growth was 81%, 30% at 1 μM, and no significant inhibition was observed at concentrations below 0.1 μM. For ZR 75.1 cells, the growth inhibition rate was 74% at 10 μM, 63% at 1 μM, and 42% at 0.1 μM[1]. |
| In vivo | In six-week-old athymic female Balb/c mice implanted with MCF-7 cell line, Ro 41-5253 (10, 30, 100, 300, and 600 mg/kg; oral gavage; once weekly; for 4 weeks) resulted in a reduction in tumor volume at doses of 10, 30, and 100 mg/kg, with no toxic side effects[2]. |
| Synonyms | Ro-41-5253, Ro 415253 |
| Molecular Weight | 484.65 |
| Formula | C28H36O5S |
| Cas No. | 144092-31-9 |
| Smiles | CCCCCCCOc1cc2c(cc1\C(C)=C\c1ccc(cc1)C(O)=O)C(C)(C)CCS2(=O)=O |
| Relative Density. | 1.154g/cm3 |
| Storage | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (165.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.81 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.